Alpha-glucosidase Inhibitors Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Alpha-glucosidase Inhibitors Market is Segmented by Drugs and Geography

Market Snapshot

alpha glucosidase inhibitors market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Middle East and Africa
Largest Market: Asia Pacific
CAGR: 0 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

  • The global alpha-glucosidase inhibitors market registered a revenue of 4069 USD million in 2018 and is expected to grow at a CAGR of 2% during the forecast period of 2019-2024.
  • The growth of alpha-glucosidase inhibitors (AGIs) is moderate, as it is considered mostly as second-line monotherapy treatment of drugs or given in combination with other first-line therapy drugs.
  • The primary driver for the growth is mostly in more carbohydrate consumption regions. China and India hold the highest market value, due to their high consumption of carbohydrates, followed by North America (Canada and the United States).

Scope of the Report

The Market is Segmented by Drugs and Geography - Growth, Trends, and Forecast (2019 - 2024)

Drug
Alpha-glucosidase Inhibitors (Value and Volume 2012-2024)
Alpha-glucosidase Inhibitors
Geography
North America
United States (Value and Volume 2012-2024)
Canada (Value and Volume 2012-2024)
Rest of North America (Value and Volume 2012-2024)
Europe
France (Value and Volume 2012-2024)
Germany (Value and Volume 2012-2024)
Italy (Value and Volume 2012-2024)
Spain (Value and Volume 2012-2024)
United Kingdom (Value and Volume 2012-2024)
Russia (Value and Volume 2012-2024)
Rest of Europe (Value and Volume 2012-2024)
Latin America
Mexico (Value and Volume 2012-2024)
Brazil (Value and Volume 2012-2024)
Rest of Latin America (Value and Volume 2012-2024)
Asia-Pacific
Japan (Value and Volume 2012-2024)
South Korea (Value and Volume 2012-2024)
China (Value and Volume 2012-2024)
India (Value and Volume 2012-2024)
Australia (Value and Volume 2012-2024)
Vietnam (Value and Volume 2012-2024)
Malaysia (Value and Volume 2012-2024)
Indonesia (Value and Volume 2012-2024)
Philippines (Value and Volume 2012-2024)
Thailand (Value and Volume 2012-2024)
Rest of Asia Pacific (Value and Volume 2012-2024)
Middle East and Africa
Saudi Arabia (Value and Volume 2012-2024)
Iran (Value and Volume 2012-2024)
Egypt (Value and Volume 2012-2024)
Oman (Value and Volume 2012-2024)
South Africa (Value and Volume 2012-2024)
Rest of Middle and Africa (Value and Volume 2012-2024)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Acarbose is the most widely prescribed drug of the other two drugs currently available.

  • Acarbose is the most widely prescribed of the three currently available (Acarbose, Miglitol, and Voglibose) alpha‐glucosidase inhibitors and has been used in the management of hyperglycemia for years.
  • Acarbose acts non‐systemically to slow down carbohydrate digestion and attenuates high levels of post‐prandial plasma glucose (PPG) – an essential manifestation in the early course of type 2 diabetes mellitus (T2DM) and a critical target for achieving glycemic control.
  • Patients take these agents at the beginning of each main meal. AGIs do not cause hypoglycemic events or other life-threatening events, even at overdoses, and cause no weight gain.
  • Despite numerous studies showing beneficial effects of acarbose as a first‐line, second‐line, and third‐line treatment option, prescribing of this drug varies worldwide, due to a perception that efficacy is limited in some ethnic and regional groups.
  • However, AGIs frequently cause loose stools and flatulence, when used at the recommended doses (i.e., usually 100 mg acarbose three times daily).
  • Since these effects are dose-related, it is advised to start the treatment with low doses and gradually increase it accordingly. The side effect of loose stools may be useful in a patient preoccupied with constipation.
alpha glucosidase inhibitors market

Asia-Pacific holds the highest market share in the alpha-glucosidase market.

  • The Asia-Pacific holds more than 50% of the market share in 2018. China is facing the largest diabetes epidemic in the world, with around 11% of its population suffering from metabolic illness, while nearly 36% are pre-diabetic.
  • In 2018, China held the largest share in the Asia-Pacific alpha-glucosidase market due to the large patient pool and high prevalence rate in the country. 
alpha glucosidase inhibitors market

Competitive Landscape

The market studied is highly fragmented into many local players in every region. The Asia-Pacific contribute to the highest market share in 2018, due to a large number of generic products in the region especially China and India. 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Drug

      1. 5.1.1 Alpha-glucosidase Inhibitors (Value and Volume 2012-2024)

        1. 5.1.1.1 Alpha-glucosidase Inhibitors

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume 2012-2024)

        2. 5.2.1.2 Canada (Value and Volume 2012-2024)

        3. 5.2.1.3 Rest of North America (Value and Volume 2012-2024)

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume 2012-2024)

        2. 5.2.2.2 Germany (Value and Volume 2012-2024)

        3. 5.2.2.3 Italy (Value and Volume 2012-2024)

        4. 5.2.2.4 Spain (Value and Volume 2012-2024)

        5. 5.2.2.5 United Kingdom (Value and Volume 2012-2024)

        6. 5.2.2.6 Russia (Value and Volume 2012-2024)

        7. 5.2.2.7 Rest of Europe (Value and Volume 2012-2024)

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume 2012-2024)

        2. 5.2.3.2 Brazil (Value and Volume 2012-2024)

        3. 5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume 2012-2024)

        2. 5.2.4.2 South Korea (Value and Volume 2012-2024)

        3. 5.2.4.3 China (Value and Volume 2012-2024)

        4. 5.2.4.4 India (Value and Volume 2012-2024)

        5. 5.2.4.5 Australia (Value and Volume 2012-2024)

        6. 5.2.4.6 Vietnam (Value and Volume 2012-2024)

        7. 5.2.4.7 Malaysia (Value and Volume 2012-2024)

        8. 5.2.4.8 Indonesia (Value and Volume 2012-2024)

        9. 5.2.4.9 Philippines (Value and Volume 2012-2024)

        10. 5.2.4.10 Thailand (Value and Volume 2012-2024)

        11. 5.2.4.11 Rest of Asia Pacific (Value and Volume 2012-2024)

      5. 5.2.5 Middle East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)

        2. 5.2.5.2 Iran (Value and Volume 2012-2024)

        3. 5.2.5.3 Egypt (Value and Volume 2012-2024)

        4. 5.2.5.4 Oman (Value and Volume 2012-2024)

        5. 5.2.5.5 South Africa (Value and Volume 2012-2024)

        6. 5.2.5.6 Rest of Middle and Africa (Value and Volume 2012-2024)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes population (2012-2024)

    2. 6.2 Type-2 Diabetes population (2012-2024)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Bayer pharma

      2. 7.1.2 Takeda

      3. 7.1.3 Pfizer

      4. 7.1.4 Glenmark pharma

      5. 7.1.5 Sun pharma

      6. 7.1.6 Torrent

      7. 7.1.7 Unichem

      8. 7.1.8 Hexalag

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Alpha-glucosidase Inhibitors Market market is studied from 2018 - 2026.

The Alpha-glucosidase Inhibitors Market is growing at a CAGR of 0% over the next 5 years.

Middle East and Africa is growing at the highest CAGR over 2021- 2026.

Asia Pacific holds highest share in 2020.

Sun Pharma, Bayer, Pfizer, Takeda are the major companies operating in Alpha-glucosidase Inhibitors Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!